Central Valley Advisors LLC Purchases 751 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Central Valley Advisors LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 12.3% in the 4th quarter, HoldingsChannel reports. The fund owned 6,871 shares of the medical research company’s stock after acquiring an additional 751 shares during the period. Central Valley Advisors LLC’s holdings in IQVIA were worth $1,350,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of IQV. Cypress Wealth Services LLC raised its position in IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock worth $244,000 after purchasing an additional 57 shares during the last quarter. Sendero Wealth Management LLC increased its stake in shares of IQVIA by 25.4% in the fourth quarter. Sendero Wealth Management LLC now owns 45,221 shares of the medical research company’s stock valued at $8,886,000 after buying an additional 9,153 shares during the period. Laurel Wealth Advisors LLC raised its position in shares of IQVIA by 3.2% during the fourth quarter. Laurel Wealth Advisors LLC now owns 4,572 shares of the medical research company’s stock worth $898,000 after acquiring an additional 140 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its stake in shares of IQVIA by 26.1% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 1,839 shares of the medical research company’s stock worth $361,000 after acquiring an additional 381 shares during the period. Finally, Community Trust & Investment Co. boosted its holdings in IQVIA by 4.9% in the fourth quarter. Community Trust & Investment Co. now owns 77,240 shares of the medical research company’s stock valued at $15,178,000 after acquiring an additional 3,634 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.8 %

Shares of NYSE:IQV opened at $197.71 on Friday. The business’s 50 day moving average is $200.93 and its 200 day moving average is $221.44. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The stock has a market cap of $35.89 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.09 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Bank of America dropped their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Redburn Atlantic began coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.